Consumer confidence rose in August to lift the markets to a higher close with the Dow gaining 56 points to 21,865. Nasdaq rose 18 points to 6,301.
On the upside
Movado Group (NYSE: MOV) reported better than expected earnings and revenue for the second quarter.
ImmunoGen (Nasdaq: IMGN) entered a strategic collaboration agreement granting Jazz Pharmaceuticals (Nasdaq: JAZZ) exclusive, worldwide rights to develop and commercialize of two early-stage, hematology-related antibody-drug conjugate programs.
Catalent (NYSE: CTLT) reported higher fourth quarter earnings and revenue that beat expectations.
On the downside
J.Jill (NYSE: JILL) reported higher second quarter earnings and revenue but investors were disappointed with the retailer's forecast.
Finish Line (Nasdaq: FINL) warned that second quarter results would fall short of expectations, cut its outlook for the current quarter and full year and adopted a shareholder rights plan.
The European Commission approved Aveo Pharmaceuticals' (Nasdaq: AVEO) advanced renal cell carcinoma treatment Fotivda but the stock price dropped.
In the broad market, declining issues barely edged out advancers by a slim margin on the NYSE while advancers outpaced decliners by nearly 9 to 8 on Nasdaq. The broader S&P 500 added 2 points to 2,446. Bitcoin jumped $228 to $4,605.
